| 摘要: |
| 我国于2011年发布的《原发性肝癌诊疗规范》有效提高了肝癌的综合诊治水平。最新发布的《原发性肝癌诊疗规范（2017年版）》在2011年版的基础上，首次引入了循证医学证据等级，规范了肝癌病理取材方法，引入了微血管侵犯的概念作为病理常规报告项目，通过实体瘤疗效评价标准修订版（mRECIST）评价抗肿瘤治疗疗效，并根据我国实际情况，提出了我国的肝癌临床分期和治疗路径。本文试对《原发性肝癌诊疗规范（2017年版）》的更新要点进行解读，供同行参考。 |
| 关键词: 肝肿瘤 肝细胞癌 诊疗规范 解读 |
| DOI：10.16781/j.0258-879x.2017.09.1085 |
| 投稿时间：2017-08-28修订日期：2017-09-11 |
| 基金项目:国家重点研发计划（2017YFA0504503），国家自然科学基金（81772529），上海市引导类科技支撑项目（16411966600）. |
|
| Interpretation of 2017 updated consensus on Standardization of Diagnosis and Treatment for Hepatocellular Carcinoma |
| WANG Jian,DONG Wei,LIU Fu-chen,GUO Xing-gang,LIU Hui* |
(Department of Hepatic Surgery(Ⅲ), Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, China
*Corresponding author) |
| Abstract: |
| The Standardization of Diagnosis and Treatment for Hepatocellular Carcinoma issued by China in 2011 has effectively improved the comprehensive diagnosis and treatment of hepatocellular carcinoma (HCC). The new edition of Standardization of Diagnosis and Treatment for Hepatocellular Carcinoma published in 2017 firstly introduced the Oxford Centre for Evidence Based Medicine (OCEBM) grades of evidence, standardized the sampling method of HCC, and emphasized microvascular invasion (MVI) as an indicator of regular pathology report. The new guideline recommends modified Response Evaluation Criteria in Solid Tumor (mR ECIST) to assess anti-tumor efficiency. Moreover, the new guideline presents the Chinese staging system and treatment roadmap for HCC according to Chinese actual situation. This paper aimed to interpret the updates of the new guideline for reference by colleagues. |
| Key words: liver neoplasms hepatocellular carcinoma guideline interpretation |
